Introductory Chapter: The Antibiotic Resistance Epidemic

*Guillermo Tellez-Isaias*

## **1. Introduction**

Antibiotic resistance is a global problem that has triggered a global human and animal health crisis worldwide. Antibiotics have changed the face of medicine and saved millions of lives, but resistant bacteria are threatening their usefulness.

The pharmaceutical industry is experiencing a shortage of new drug development due to declining economic incentives and demanding regulatory requirements. Governing agencies worldwide have identified several "super-bugs," bacteria resistant to all antibiotics known by man.

A more comprehensive approach to bacterial infection is required, including alternatives to conventional antibacterial agents.

Several antibiotics were discovered from the 1950s to the 1970s to cure previously incurable diseases, including tuberculosis and syphilis [1]. Since then, no new antibiotic classes have been discovered, which is concerning given the bacterial resiliency [2] and the continuous abuse and misuse of antibiotics [3].

Alexander Fleming recognized the phenomena of resistance to antimicrobial agents, by the misuse of antibiotics, in 1945 when he stated, "The time may come when anyone in the shops can buy penicillin. Then there is the danger that the ignorant man may easily under-dose himself and by exposing his microbes to nonlethal quantities of the drug make them resistant" [4].

In the absence of novel and more potent drugs, we risk a future where minor injuries and illnesses can be fatal and essential operations like surgery and chemotherapy become unmanageable. Antimicrobial resistance poses a serious threat to our way of life and could lead to a global pandemic if we don't act to combat it. Longer hospital stays and higher medical costs are now the results of antimicrobial resistance [5].

Antibiotic resistance is eroding our ability to treat bacterial illnesses. Infections resistant to most, if not all, current medicines are becoming common. The nature of significant acute bacterial infections and the economic realities of this field makes developing novel antibacterial medication difficult.

Because of the induction, amplification, and transmission of aspects of antimicrobial resistance among microbes, adequate management of a novel antibacterial agent is required for both the patient and the community when a new antibacterial agent is introduced. Furthermore, most antibiotic treatment regimens are brief (sometimes lasting only a week or two), and antimicrobial management aims to reduce the use of broader spectrum agents whenever possible to retain their usefulness, lowering the need for newer agents to enter the market.

In contrast, in many other treatment areas, such as diabetes, hypertension, and hyperlipidemia, long-term daily usage by patients does not add to the agent's loss of efficacy, and there is no medical reason to delay administration. While antimicrobial stewardship is critical, it will almost certainly diminish the economic benefits for a medication developer. Financial pressures associated with the development of antimicrobial medicines are not new [6].

There aren't enough reasons to invest in developing new antimicrobials under the current intellectual property innovation system. Since 1980, pharmaceutical corporations have made investments in cancer and chronic disease treatments for three reasons:


It is as simple as that. Where is the profit in a lost war?

Like eukaryotes, prokaryotes, including bacteria and other microorganisms, have membranes surrounding a droplet of cytoplasm. Prokaryotes acquire nutrients, communicate, excrete, and even process information in a "neurological" way [7, 8]. They can detect the presence of nutrients, toxins, and predators and adopt powerful escape techniques to preserve their viability [9]. From the evolutionary standpoint, bacteria have millions of years in advance against eukaryotes.

#### **2. Novel alternatives to combat super-bugs**

In 1908 Eli Metchnikoff obtained the Nobel Prize and was regarded as the originator of innate immunity, offering the breakthrough idea of consuming live bacterial cultures (yogurt) to improve the health and longevity of people more than a century ago [6, 10]. This principle is more appropriate than ever, as many antibiotic-resistant microorganisms threaten animal and human health [11].

In some countries around the world, pressures from society have resulted in establishing guidelines on antibiotic use in the feedstock industries. In other countries, like in the USA, it has become a commercial strategy for poultry companies and fast-food restaurants to label their products with no antibiotics ever (NAE). A similar commercial approach is observed in Brazil, which has dominated the chicken meat export market for over a decade, simply listening to the demands of countries in Europe, Asia and the middle east. Food animal production systems such as the poultry industry have been using alternative antibiotics to enhance disease resistance and productivity. According to new studies, nutritional treatments for stress, disease, and chronic inflammation may be more effective than antibiotics in some cases [12–14].

Disease resistance improvement in non-antibiotic raised animals has been shown to benefit animal products' health, welfare, production, and food safety. Alternative feed additives are being researched and developed in response to rising customer

*Introductory Chapter: The Antibiotic Resistance Epidemic DOI: http://dx.doi.org/10.5772/intechopen.105143*

demand to remove growth-promoting antibiotics. Some of those alternatives include nutraceuticals such as probiotics [15, 16]; prebiotics [17]; organic acids [18, 19]; Phytochemicals [20–22]; enzymes [23, 24]; Vaccines and immunoglobulins [25, 26]. Innovative methodologies and cutting-edge technologies, like quorum sensing and quantum mechanics approaches, have the potential to shift the balance and help to minimize the epidemic problem in the future.

## **Conflict of interest**

The author declares no conflict of interest.

## **Author details**

Guillermo Tellez-Isaias Department of Poultry Science, University of Arkansas, Fayetteville, AR, USA

\*Address all correspondence to: gtellez@uark.edu

© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## **References**

[1] Aminov RI. A brief history of the antibiotic era: Lessons learned and challenges for the future. Frontiers in Microbiology. 2010;**1**:134

[2] Carvalho G, Forestier C, Mathias J-D. Antibiotic resilience: A necessary concept to complement antibiotic resistance? Proceedings of the Royal Society B. 2019;**286**(1916):20192408

[3] Ventola CL. The antibiotic resistance crisis: Part 1: Causes and threats. Pharmacy and Therapeutics. 2015;**40**:277

[4] Fleming A. Penicillin: Nobel Lecture, December 11 1945. pp. 83-93

[5] Slama TG. Gram-negative antibiotic resistance: There is a price to pay. Critical Care. 2008;**12**(4):1-7

[6] Kaufmann SH. Immunology's foundation: The 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff. Nature Immunology. 2008;**9**:705-712

[7] Desvaux M, Hébraud M, Talon R, Henderson IR. Secretion and subcellular localizations of bacterial proteins: A semantic awareness issue. Trends in Microbiology. 2009;**17**:139-145. DOI: 10.1016/j.tim.2009.01.004

[8] Lazcano A, Peretó J. Prokaryotic symbiotic consortia and the origin of nucleated cells: A critical review of Lynn Margulis hypothesis. Biosystems. 2021;**204**:104408. DOI: 10.1016/j. biosystems.2021.10440

[9] Liversidge A. Bacterial consciousness: Why spirochetes think as we do. Omni. 1993;**16**:10-11

[10] Gordon S. Elie Metchnikoff: Father of natural immunity. European Journal of Immunology. 2008;**38**:3257-3264

[11] Pollack A. To Fight 'Superbugs,' Drug Makers Call for Incentives to Develop Antibiotics. Vol. 20. New York Times; 2016

[12] Björkman I, Röing M, Sternberg Lewerin S, Stålsby Lundborg C, Eriksen J. Animal production with restrictive use of antibiotics to contain antimicrobial resistance in Sweden—A Qualitative Study. Frontiers in Veterinary Science. 2021;**7**:1197

[13] Wang B, Ye X, Zhou Y, Zhao P, Mao Y. Glycyrrhizin attenuates salmonella typhimurium-induced tissue injury, inflammatory response, and intestinal dysbiosis in C57BL/6 mice. Frontiers in Veterinary Science. 2021;**8**:648698. DOI: 10.3389/ fvets.2021.648698

[14] Chalvon-Demersay T, Luise D, Floc'h L, Tesseraud S, Lambert W, Bosi P, et al. Functional amino acids in pigs and chickens: Implication for gut health. Frontiers in Veterinary Science. 2021;**8**:496

[15] Adhikari B, Hernandez-Patlan D, Solis-Cruz B, Kwon YM, Arreguin MA, Latorre JD, et al. Evaluation of the antimicrobial and anti-inflammatory properties of bacillus-dfm (norumTM) in broiler chickens infected with salmonella enteritidis. Frontiers in Veterinary Science. 2019;**6**:282

[16] Hernandez-Patlan D, Solis-Cruz B, Latorre JD, Merino-Guzman R, Morales Rodriguez M, Ausland C, et al. Whole genome sequence and interaction analysis in the production of six enzymes from the three Bacillus strains present in a commercial direct fed microbial (NorumTM) using a Bliss independence test. Frontiers in Veterinary Science; **9**:784387. DOI: 10.3389/fvets.2022.784387

*Introductory Chapter: The Antibiotic Resistance Epidemic DOI: http://dx.doi.org/10.5772/intechopen.105143*

[17] Praxedes-Campagnoni I, Vecchi B, Gumina E, Hernandez-Velasco X, Hall JW, Layton S. Assessment of novel water applied prebiotic to evaluate gut barrier failure and performance in two commercial trials in Brazil. A pilot study with an economic perspective. Frontiers in Veterinary Science. 2021;**8**:652730. DOI: 10.3389/fvets.2021.652730

[18] Mani-López E, Garcia H, López-Malo A. Organic acids as antimicrobials to control Salmonella in meat and poultry products. Food Research International. 2012;**45**:713-721

[19] Gomez-Osorio L-M, Yepes-Medina V, Ballou A, Parini M, Angel R. Short and medium chain fatty acids and their derivatives as a natural strategy in the control of necrotic enteritis and microbial homeostasis in broiler chickens. Frontiers in Veterinary Science. 2021;**8**:773372. DOI: 10.3389/ fvets.2021.773372

[20] Asakura H, Nakayama T, Yamamoto S, Izawa K, Kawase J, Torii Y, et al. Long-term grow-out affects campylobacter Jejuni colonization fitness in coincidence with altered microbiota and lipid composition in the cecum of laying hens. Frontiers in Veterinary Science. 2021;**8**:657

[21] Anderson RC, Levent G, Petrujki'c BT, Harvey RB, Hume ME, He H, et al. Antagonistic effects of lipids against the anti-escherichia coli and anti-salmonella activity of thymol and thymol-beta-dglucopyranoside in porcine gut and fecal cultures in vitro. Frontiers in Veterinary Science. 2021;**8**:773372. DOI: 10.3389/ fvets.2021.773372

[22] Park I, Goo D, Nam H, Wickramasuriya SS, Lee K, Zimmerman NP, et al. Effects of dietary maltol on innate immunity, gut health, and growth performance of broiler

chickens challenged with Eimeria maxima. Frontiers in Veterinary Science. 2021;**8**:508

[23] Nusairat B, Wang J-J. The effect of a modified GH11 xylanase on live performance, gut health, and clostridium perfringens excretion of broilers fed corn-soy diets. Frontiers in Veterinary Science. 2021;**8**:523

[24] Li H, Yin J, He X, Li Z, Tan B, Jiang Q, et al. Enzyme-treated soybean meal replacing extruded full-fat soybean affects nitrogen digestibility, cecal fermentation characteristics and bacterial community of newly weaned piglets. Frontiers in Veterinary Science. 2021;**8**:639039. DOI: 10.3389/fvets.2021.639039

[25] Juárez-Estrada MA, Tellez-Isaias G, Sánchez-Godoy FD, Alonso-Morales RA. Immunotherapy with egg yolk eimeria sp.-specific immunoglobulins in SPF leghorn chicks elicits successful protection against Eimeria Tenella infection. Frontiers in Veterinary Science. 2021;**8**:758379. DOI: 10.3389/ fvets.2021.758379

[26] Jabif MF, Gumina E, Hall JW, Hernandez-Velasco X, Layton S. Evaluation of a novel mucosal administered subunit vaccine on colostrum IgA and serum IgG in sows and control of enterotoxigenic escherichia coli in neonatal and weanling piglets: Proof of concept. Frontiers in Veterinary Science. 2021;**8**:89

## **Chapter 2**
